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Abstract 
 
Tissue factor (TF), also known as thromboplastin or coagulation factor III, is the 
major trigger of the coagulation cascade and thereby crucially involved in the 
maintenance of vascular hemostasis. By binding factor VIIa, the resulting TF:VIIa 
complex activates the coagulation factors IX and X ultimately leading to fibrin and clot 
formation. In the vessel wall, TF expression and activity is detectable in vascular 
smooth muscle cells and fibroblasts and, at a much lower level, in endothelial cells, 
and can be induced by various stimuli including cytokines, biogenic amines, or 
growth factors. In addition, TF is found in the bloodstream in circulating cells such as 
monocytes or leukocytes, in TF containing microparticles, and as a soluble spicing 
isoform. Besides its well known extracellular role as a trigger of coagulation, TF also 
functions as a transmembrane receptor, and TF dependent intracellular signalling 
events regulate the expression of genes involved in cellular responses such as 
proliferation and migration. TF indeed appears to be involved in the pathogenesis of 
neointima formation and tumor growth, and increased levels of TF have been 
detected in patients with cardiovascular risk factors or coronary artery disease as 
well as in those with cancer. Therefore, pharmacological or genetic inhibition of TF 
may be an attractive target for the treatment of cardiovascular disease and cancer. 
Different strategies for inhibition of TF have been developed such as inhibition of TF 
expression and blockade of TF action. Clinical applications of such strategies need to 
be tested in appropriate trials, in particular for evaluating the advantages of targeted 
versus systemic delivery of the inhibitors. 
 
 
1. Tissue factor: structure and function 
 
1.1. TF protein structure 
The TF (thromboplastin, CD142) gene located on chromosome 1 at p21-22 spans a 
12.4 kb region and contains six exons encoding a single transmembrane polypetide 
chain composed of 263 amino acids (Kao et al., 1988; Mackman et al., 1989; 
Morrissey et al., 1989; Scarpati et al., 1987). The TF protein is divided into three 
domains: an extracellular (219 amino acids), a membrane-spanning (23 amino acids) 
and a cytoplasmatic (21 amino acids) region (Breitenstein et al., 2010). TF is 
considered a class I integral membrane protein since the amino-terminus of the 
protein is located extracellularly while the cytoplasmatic tail contains the carboxy-
terminus. Mobility studies on sodium dodecyl sulfate gels reveal that the molecular 
weight of the fully glycosylated protein is about 45’000 kDa (Broze et al., 1985). The 
extracellular domain provides two high affinity sites for the binding of factor VII to TF. 
This binding is crucial for induction of the conformal changes required to induce the 
catalytic activity of factor VII (Edgington et al., 1991; Rehemtulla et al., 1991). In 
addition, anchoring of the TF protein to the membrane via the hydrophobic 
transmembrane domain has been demonstrated to be essential for procoagulant 
activity of the TF protein. However, the nature of the anchoring domain does not 
seem to play a role (Paborsky et al., 1991). Indeed, deletion of the cytoplasmtic tail is 
not paralleled by an impaired TF procoagulant activity (Paborsky et al., 1991). 
Therefore, recent studies focussed on possible non-hemostatic functions of this 
domain. Experiments performed mainly in fibroblasts and cancer cell lines revealed 
that phosphorylation of the cytoplasmatic tail activates intracellular signaling 
pathways and induces cellular responses which are described in the following 
chapter. 
In 2003, an alternatively spliced (as) isoform of TF mRNA lacking the fifth exon and 
exhibiting a frameshift mutation in the carboxy-terminal region was characterized 
(Bogdanov et al., 2003). This TF protein lacks membrane anchorage and is 
detectable in the plasma as a soluble TF protein. While the asTF protein has been 
described in different species and cell types, its contribution to the TF procoagulant 
activity in plasma as well as thrombus formation in vivo remains barely understood 
(Bogdanov et al., 2006; Mackman, 2007). 
 
1.2. Tissue factor: key trigger of coagulation 
In intact vessels, blood circulates as a fluid due to the physiological balance between 
natural procoagulant and anticoagulant factors. The clotting cascade defines a 
complex system of zymogens and enzymatic reactions designed to limit blood loss 
and ultimately restore vascular integrity by formation of a clot following vessel injury. 
Initially, initiation of coagulation was thought to be triggered by two distinct pathways: 
the intrinsic, or contact activation pathway and the extrinsic, or tissue factor (TF) 
pathway. Even though the two pathways are independently activated, the distinction 
between both of them has been blurred since they share a final common pathway 
and, in addition, there is crosstalk between the two systems. The intrinsic pathway is 
activated when blood or plasma comes in contact with subendothelial connective 
tissue or negatively charged surfaces and involves circulating factors such as factor 
XII, factor XI, factor IX, prekallikrein, and high molecular weight kininogen (Gailani 
and Renne, 2007). However, in has been questioned that this pathway is required for 
maintenance of normal haemostasis, since congenital deficiency in the involved 
factors, for example factor XII, does not result in an increased bleeding tendency or 
clinically appearant pathologies in humans. 
Coagulation through the TF pathway is activated when blood interacts with a TF 
expressing cell surface, such as it occurs after endothelial erosion, plaque rupture, or 
other vascular injury (Fig. 1). The initial step consists in the reversible binding of the 
zymogen factor VII (FVII) or the activated FVII (FVIIa) to membrane-bound TF 
(Mackman, 2009; Mackman et al., 2007), resulting in the formation of both TF:FVII 
and TF:VIIa complexes. Only the latter, however, possesses the enzymatic activity 
required for further activation of downstream proteases. Once bound to TF, the 
inactive FVII is converted to FVIIa via limited proteolysis by several plasma 
proteases, such as XIIa, Xa, Ixa, or thrombin, generating a positive feedback loop 
(Steffel et al., 2006). The TF:FVIIa complex is indeed a potent activator of the 
coagulation cascade and is composed of TF acting as a cofactor with regulatory 
functions, and the serine protease FVIIa exerting catalytic functions (Breitenstein et 
al., 2010). The TF:VIIa complex activates factor IX to factor IXa which in association 
with VIIIa catalyzes the conversion of factor X to Xa. In addition, factor X is directly 
converted to factor Xa by the TF:FVIIa complex. Factor Xa in association with factor 
Va and divalent calcium forms the so called prothrombinase complex which cleaves 
prothrombin to form thrombin (Breitenstein et al., 2010). Thrombin exerts direct 
effects on coagulation through conversion of fibrinogen to fibrin, activation of 
platelets, and activation of various proteases of the coagulation cascade such as 
FVII, FXI, and FV representing an important auto-feedback loop. Besides its well 
known role in clot formation, the functions of thrombin extend from coagulation to 
vascular remodelling by stimulating proliferation of vascular smooth muscle and 
endothelial cells as well as secretion of growth factors ultimately leading to 
restoration of vascular integrity (Ferrara and Davis-Smyth, 1997; Maragoudakis et al., 
2002; Tsopanoglou et al., 2002; Tsopanoglou et al., 2004). 
 
1.3.  Tissue factor: a signaling receptor 
The tight link between hemostasis and progression of vascular alterations such as 
inflammation or atherosclerosis provides evidence for complex interactions between 
the coagulation cascade and vascular pathophysiology. Mainly because of its 
similarity to class II cytokine receptors recent studies suggested a non-hemostatic 
role of TF in different biological processes through induction of intracellular signaling 
events (Bazan, 1990). The following chapter provides an overview of TF mediated 
cell signaling (Fig. 1). 
Evidence for TF:VIIa induced signaling is derived from experiments in which FVIIa 
binding to TF was shown to induce intracellular calcium transients in different types of 
TF expressing cells (Camerer et al., 1996; Rottingen et al., 1995). This observation 
was followed by studies demonstrating that binding of factor VIIa to TF induces the 
activation of  the three major mitogen activated protein (MAP) kinase family members 
p38 MAP kinase, p42/p44 MAP kinase, and c-Jun N-terminal kinase (JNK) (Camerer 
et al., 1999; Poulsen, et al., 1998). In fibroblasts, the TF-FVIIa induced activation of 
Src-like kinases and PI3-kinase leads to activation of the downstream Rho-like 
guanosine triphosphatases Rac and Cdc42 resulting in cytoskeletal reorganization 
(Versteeg et al., 2000).  
Hence, by activating different kinases involved in signal transduction, the TF:VIIa 
complex regulates the transcription of numerous genes involved in physiological and 
pathophysiological processes such as cell migration, cell growth, or apoptosis. 
Indeed, binding of factor VIIa to TF induces activation of key transcription factors 
such as Egr-1 or nuclear factor kappa B and the activation of the RNA polymerase A 
(Camerer, et al., 1999; Pendurthi et al., 1997). Moreover, microarray analysis of the 
gene expression profiles revealed increased mRNA levels of growth factors (i.e. 
connective tissue growth factors CCN1 and CCN2, fibroblast growth factor 5) and 
inflammatory cytokines (i.e. interleukin-1, interleukin-8) following factor VIIa and TF 
interaction (Camerer et al.,2000; Pendurthi, et al., 2000).  
Interestingly, induction of signal transduction events was demonstrated to depend on 
the catalytic activity of factor VIIa, because inactivated factor VII or anti-TF antibodies 
blunt these effects (Camerer et al., 1999; Camerer et al., 1996; Pendurthi et al, 2000; 
Poulsen et al., 1998). Consistent with this observation, the TF:VIIa complex initiates 
intracellular signalling via G-protein-coupled protease-activated receptors (PARs) 
(Riewald & Ruf, 2002; Siegbahn, 2000). Currently, 4 different PARs have been 
characterized: PAR1, PAR2, PAR3, and PAR4. There is growing evidence that 
TF:VIIa signaling is mediated mainly by PAR2 and to a lesser extent by PAR1, while 
PAR3 and PAR4 do not seem to be involved. For instance, in fibroblasts derived from 
PAR1 knockout mice, the FVIIa induced response only occurred when TF and PAR2 
where co-expressed (Camerer et al., 2000). Moreover, data obtained in a carcinoma 
cell line demonstrate that antibodies targeting PAR2, but not PAR1, blunt TF:VIIa 
induced IL-8 expression and smooth muscle cell migration (Marutsuka et al., 2002). 
Even though not essential for TF:VIIa induced activation of MAP kinases and gene 
expression, the cytoplasmic domain of TF is implicated in cytoskeletal organization 
and cell migration (Bromberg, Konigsberg, Madison, Pawashe, & Garen, 1995; 
Mueller & Ruf, 1998). Protein kinase C mediated phosphorylation of the 
cytoplasmatic domain at the serine residues Ser253 and Ser258 enables the 
interaction of the cytoplasmatic tail with the actin-binding protein 280 thereby 
regulating actin filament rearrangement (Ott et al., 1998; Zioncheck et al., 1992). 
Studies performed in mice lacking the cytoplasmatic tail of TF demonstrated the 
crucial role of the cytoplasmatic domain for vascular smooth muscle migration and 
vascular remodelling after injury in vivo (Ott et al., 2005). 
Since increasing evidence suggests an essential role of TF as an important signal 
transducer beyond its well-known functions in coagulation, developing specific 
inhibitors that suppress either TF:VIIa mediated signaling or its coagulant function 
may offer interesting therapeutic approaches for the treatment of TF associated 
diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Tissue factor in cardiovascular disease 
 
2.1. TF distribution 
2.1.1. Vascular TF 
Under normal hemostatic conditions, TF is only barely expressed in endothelial cells 
(Fig. 2). Inflammatory cytokines such as tumour necrosis factor-α (TNF-α) (Holy et 
al., 2005) or interleukin-1β (Napoleone et al., 1997) enhance TF expression. This 
induction of TF protein is mainly mediated by the mitogen-activated protein (MAP) 
kinases p38, extracellular-signal-regulated kinase (ERK), and c-Jun N-terminal 
kinase (JNK) which activate transcription factors such as nuclear factor kappa B, 
activator protein-1, or early growth-response gene product-1, all of them involved in 
transcription of the TF gene (Bavendiek et al., 2002; Mackman, 1997; 
Mechtcheriakova et al., 2001). Depending on the stimulus, induction of TF 
expression occurs via activation of either all three MAP kinases (Holy et al., 2009; 
Steffel et al., 2006; Steffel et al., 2005) or only a single pathway (Mechtcheriakova et 
al., 2001). Protein kinase C as well as the Rho-kinase pathway have also been 
shown to mediate the induction of endothelial TF expression (Eto et al., 2002; 
Mechtcheriakova et al., 2001; Zhang et al., 2007). Whereas the MAP kinase, Rho-
kinase, and protein kinase C pathways regulate TF expression in a positive manner, 
the phosphoinositide 3 kinase pathway exerts a negative regulatory effect on TF 
expression (Blum et al., 2001; Steffel et al., 2005). Indeed, downstream targets of 
phosphoinositide 3 kinase are able to regulate TF expression at both the 
transcriptional and the translational level. Akt and glycogen synthase kinase 3β 
regulate TF transcription (Eto et al., 2005), whereas the mammalian target of 
rapamycin and p70S6 kinase inhibit TF translation (Guba et al., 2005; Steffel et al., 
2005). An additional mechanism affecting the regulation of TF protein expression is 
stabilization of TF messenger RNA. A recent study in endothelial cells demonstrated 
that a decrease in TF promoter activity may be counteracted by an increased TF 
mRNA stability leading to an overall enhanced TF protein expression (Holy et al., 
2009). 
        In contrast to endothelial cells, vascular smooth muscle cells constitutively 
express TF providing a hemostatic barrier after vascular injury (Fig. 2; Breitenstein et 
al., 2008; Camici et al., 2006; Schecter et al., 1997; Wilcox et al., 1989). Similar to 
endothelial cells, TF expression in vascular smooth muscle cells is enhanced by 
several receptor ligands such as CD40 ligand, histamine, thrombin, bacterial 
endotoxin, oxidized LDL, or C-reactive protein (Camici et al., 2006; Kamimura et al., 
2004; Llorente-Cortes et al., 2004; Taubman et al., 1993; Wu et al., 2008). Even 
though not investigated to the same extent as in endothelial cells, the MAP kinase 
and phosphoinositide 3-kinase pathways regulate TF expression also in vascular 
smooth muscle cells. 
 
2.1.2. Blood-borne TF 
More recently, TF has been detected at low levels in plasma and urine, and these 
levels increase in several inflammatory disease conditions such as atherosclerosis, 
disseminated intravascular coagulation, glomerulonephritis, sepsis, or diabetes.  
Monocytes are thought to represent a major source of the plasmatic TF pool. 
Monocytes constitutively express TF and its expression is enhanced after exposure 
to numerous inflammatory mediators (Cai et al., 2007; Cermak et al., 1993; Guha & 
Mackman, 2002; Lewis et al., 1995; Luyendyk et al., 2008; Mach et al., 1997). 
Indeed, elevated levels of TF have been measured in plasma during septic states 
and may account for the thrombotic complications encountered in those patients 
(Osterud & Bjorklid, 2001; ten Cate et al., 2000). Endotoxin-induced TF expression is 
mediated via MAP kinases (Guha & Mackman, 2002; Lewis et al., 1995) and the 
consecutive activation of the transcription factors EGR-1, c-Fos/c-Jun, and nuclear 
factor kappa B. In addition, endotoxin also increases TF mRNA stability (Brand et al., 
1991). 
TF has also been described in circulating granulocytes. Eosinophils, neutrophils, and 
basophils have been found to express TF (Kambas et al., 2008; Maugeri, Brambilla 
et al., 2006; Maugeri et al., 2006; Moosbauer et al., 2007; Muller et al., 2003). Both 
the trancription and the translocation of TF to the cell surface are enhanced upon 
stimulation of these cells with granulocyte/macrophage colony-stimulating factor or 
platelet-activating factor (Moosbauer et al., 2007). These findings may explain the 
pro-thrombotic state associated with hypereosinophilia (Cugno et al., 2009). 
Even though TF-containing platelets have been described by several groups (Falati 
et al., 2003; Muller et al., 2003; Panes et al., 2007; Perez-Pujol et al., 2005; Zillmann 
et al., 2001) the role of platelet derived TF remains debatable (Butenas et al., 2005). 
In platelets, TF is encountered in different compartments including the membrane, 
the matrix of α-granules, and the canalicular system; it is translocated to the cell 
surface upon activation by different agonists. Since TF messenger RNA is not found 
in human megakaryocytes, the source of platelet derived TF remains a matter of 
debate. One hypothesis suggests that TF containing microparticles derived from 
activated monocytes, leucocytes (Rauch et al., 2000), or endothelial cells (Aras et al., 
2004; Camera et al., 2003) fuse with the platelet membrane through a receptor 
mediated process (Falati et al., 2003; Rauch et al., 2000) and thereby deliver TF into 
platelets. However, other studies demonstrated the presence of a spliced TF mRNA 
in activated human platelets confirming an increased TF protein synthesis and 
activity in ADP stimulated platelets (Camera et al., 2003). 
TF containing microparticles have been well characterized in plasma. Besides 
endothelial and vascular smooth muscle cells (Abid Hussein et al., 2003; Lechner et 
al., 2007; Moosbauer et al., 2007; Schecter et al., 2000), monocytes and platelets are 
the main source of TF containing microparticles (Hron et al., 2007; Siddiqui et al., 
2002). Despite studies demonstrating the role of microparticle derived TF in the 
thrombin generation in vitro (Sturk-Maquelin et al., 2003), doubts remain about its 
contribution to thrombus formation in vivo (Biro et al., 2003; Day et al., 2005).  
The full-length form of TF mRNA contains 6 exons and splicing of exon 5 results in a 
frame-shift mutation generating a soluble alternatively spliced TF protein lacking the 
transmembrane domain (Bogdanov et al., 2003). Apart from plasma, alternatively 
spliced TF has been found in several tissues and cell types including the lung, 
placenta, vascular smooth muscle cells, and keratinocytes. Whereas it remains 
unclear whether alternatively spliced TF exerts pro-coagulant activity (Szotowski et 
al., 2005) more recent reports have revealed a role of alternatively spliced TF in 
angiogenesis by promoting endothelial cell migration and differentiation (Censarek et 
al., 2007; Y. He et al., 2008). 
 
2.1.3. Cardiac TF  
In contrast to skeletal myocytes, cardiac myocytes express the full length form of TF 
under basal conditions (Hartzell et al., 1989; Mackman et al., 1993). Studies 
performed in mice expressing low levels of TF revealed a potential role of TF in the 
maintenance of cardiac hemostasis, since these mice had increased cardiac 
hemorrhages and hemosiderin deposition ultimately leading to cardiac fibrosis and a 
reduction in left ventricular function as compared to wild type animals (Pawlinski et 
al., 2002). Phagocytosis of hematin derived from hemorrhaging erythrocytes is 
thought to play a key role in this process. Interestingly, mice lacking factor IX had 
normal hearts, underlining the specific role of the TF:VIIa complex in hemostatic 
protection of the heart. 
 
2.2. TF in cardiovascular disease 
2.2.1. TF in thrombus formation 
Although TF is critically involved in initiation of the coagulation cascade, questions 
regarding the role and contribution of the different TF pools in arterial thrombus 
formation remain open. 
Under normal hemostatic conditions, TF is constitutively expressed in the vascular 
smooth muscle layer of the media and in fibroblasts present in the vessels as well as 
in the adventitia surrounding the vessels (Drake et al., 1989; Fleck et al., 1990). 
Hence, disruption of blood vessel integrity promotes the interaction between 
circulating FVII and the vascular TF pool leading to initiation of the clotting cascade 
(Fig. 2). Moreover, the release of inflammatory triggers following vascular injury or 
plaque rupture induces the expression of TF in endothelial cells as well as in 
circulating cells thereby potentiating a full coagulation response (Steffel et al., 2006). 
In contrast to the initiation phase of coagulation, the mechanisms promoting the 
propagation of clot growth are not as evident yet. 
Blood-borne TF may contribute to the propagation of the clotting reaction. This 
consideration is based on the fact that the maintenance of coagulation requires a 
constant activity of TF as a cofactor and that the formed fibrin clot isolates and 
prevents the initially formed TF:VIIa complexes from reacting with circulating new 
inactive coagulation factors (Hathcock & Nemerson, 2004). This hypothesis is 
supported by the observation that TF is detected at very low levels in the blood 
unable to trigger a coagulant response whereas the TF concentration reaches 
functionally significant levels on the surface of a forming thrombus (Bogdanov et al., 
2003; Chou et al., 2004; Jesty & Beltrami, 2005). In addition, TF has been found 
embedded in murine (Day et al., 2005; Hoffman et al., 2006) and human (Wysokinski 
et al., 2004) thrombi. The role of blood-borne TF in coagulation is strengthened by an 
in vitro study demonstrating that the sub-picomolar TF concentrations found in blood 
cause an increase in thrombin formation under flow, but not under no-flow conditions 
(Okorie et al., 2008). 
On the other hand, recent experiments performed in mathematical as well as whole 
blood models revealed different stages of TF requirement in the clotting process and 
showed that the propagation of coagulation is TF independent once thrombin has 
started to be formed (Orfeo et al., 2005). By abrogating TF activity with specific 
antibodies targeting either VIIa or TF, 3 phases in the clotting process could be 
distinguished: a first short (<10 seconds) period of absolute TF:VIIa dependence; a 
second period (10-240 seconds) of partial TF:VIIa dependence that decreases with 
the progress of the reaction, and a period which is TF:VIIa independent beginning 
after 2 minutes. In addition, this study revealed that the initial activation of 
procoagulant proteases by the TF:VIIa complex is sufficient to maintain a pool of 
activated procoagulant catalysts able to maintain a sustained coagulation response 
in a TF independent manner. 
Since venous thrombosis is not always associated with vessel damage, circulating 
TF may play an important role in this pathology. In a model of jugular vein thrombosis 
inhibition of TF reduced thrombus growth in the uninjured vein (Himber et al., 2003). 
However, in another study, hematopoietic cell-derived TF did not affect venous 
thrombosis in an inferior vena cava thrombosis model in the mouse (Day et al., 
2005). Hence, the exact role of the different TF pools and their contributions to the 
propagation of clot formation remains controversial and further studies are definitely 
required. 
 2.2.2. TF in inflammation and atherosclerosis 
Inflammation is tightly linked to the development of atherosclerosis (Hansson, 2005). 
Elevated levels of inflammatory cytokines known to induce TF expression such as 
TNF-α and interleukins are observed in early atherosclerotic lesions. In the early 
stages of atherogenesis, TF mRNA and antigen is expressed in macrophages 
(Thiruvikraman et al., 1996; Wilcox et al., 1989), and as the lesions progress, TF is 
increasingly expressed in other cell types such as endothelial cells and smooth 
muscle cells (Fig. 2). Within the necrotic core (Marmur et al., 1996), it is 
predominantly associated with TF containing microparticles released by foam cells, 
monocytes, lymphocytes, and smooth muscle cells; in addition, it is detected in the 
extracellular space (Mallat et al., 2000). During plaque rupture, the content of the 
core comes in contact with the circulating blood and TF present within the plaque as 
well as expressed by activated endothelial and smooth muscle cells triggers 
thrombus formation leading to an acute vascular event. Indeed, higher levels of TF 
are measured in atherosclerotic plaques of patients suffering from an acute coronary 
syndrome as compared to patients exhibiting stable angina (Annex et al., 1995). 
Recent studies implicate that TF and TF:VIIa signaling may also play a role in the 
pathogenesis of atherosclerosis. The TF:VIIa complex has been shown to be a strong 
chemotactic stimulus for vascular smooth muscle cells (Sato et al., 1996). Inhibition of 
TF:VIIa by overexpression of tissue factor pathway inhibitor leads to a consecutive 
reduction of vascular smooth muscle cell migration and impairs vascular remodeling 
in the mouse in vivo (Sato et al., 1999; Singh et al., 2001). Since TF:VIIa mediated 
cell signalling induces a number of gene products involved in cell proliferation and 
migration, it is very likely that similar effects occur in TF expressing cells within 
atherosclerotic lesions. TF:VIIa signalling indeed enhances the expression of the 
connective tissue growth factors CCN1 and CCN2 in fibroblasts and vascular smooth 
muscle cells. Similar to TF, CCN1 and CCN2 mRNA levels are highly expressed in 
atherosclerotic lesions of apoE-/- mice and in human atherosclerotic plaques (Oemar 
& Luscher, 1997; Oemar et al., 1997). Hence, it is conceivable that by inducing the 
expression of CCN1 and CCN2 and possibly other mediators as well, TF:VIIa 
promotes plaque progression via enhanced extracellular matrix accumulation and 
vascular smooth muscle cell proliferation. In addition, a role of CCN1 and CCN2 in 
monocyte and platelet adhesion to the subendothelial matrix after endothelial injury 
has also been described (Jedsadayanmata et al., 1999; Schober et al., 2002). 
In response to inflammatory mediators, TF transcription can be induced in different 
cell types. On the other hand, TF expressed on these cells appears to regulate the 
inflammatory response. During sepsis, the TF pathway induces a lethal inflammatory 
exacerbation independent of thrombin generation and clot formation (Creasey et al., 
1993; Taylor et al., 1991). Inhibition of the TF:VIIa complex is paralleled by a 
decrease in interleukin secretion and a reduction in inflammatory infiltrations in 
several tissue during sepsis (Miller et al., 2002). This finding is confirmed by the 
observation that mice suffering from sepsis and expressing low TF levels display 
reduced interleukin levels and an increased survival compared with control mice 
(Pawlinski et al., 2004). Studies performed in PAR2 deficient mice suggest that the 
pro-inflammatory TF:VIIa signaling response is likely mediated via PAR2 (Pawlinski 
et al., 2004). However it is worth noting that deficiency in PAR1 or PAR2 alone has 
no effect and that a reduction in inflammation and mortality is only observed in the 
context of a combined inhibition of thrombin generation and PAR2 receptor, 
indicating a tight link between coagulation and inflammation. 
 
2.2.3. TF in acute coronary syndromes  
High levels of TF have been detected in coronary atherectomy specimens from 
patients with unstable angina or myocardial infarction (Ardissino et al., 1997). In line 
with this, plasma TF levels are elevated in patients with acute coronary syndromes 
compared with controls (Misumi et al., 1998; Soejima et al., 1996) and correlate with 
an unfavourable outcome in these patients (Soejima et al., 1999). In addition, 
patients with unstable angina or non-ST-elevation myocardial infarction and a high 
TIMI score (≥4) exhibit increased TF plasma levels as compared to those with a low 
TIMI score (<3) (Lee et al., 2005). 
Percutaneous transcoronary angioplasty and coronary stent implantation has 
become the gold standard in the treatment of culprit lesions in acute coronary 
syndromes. The local inflammatory reaction following balloon dilatation and stent 
implantation (Brunetti et al., 2007) induces the release of TF from the dissected 
plaque. Thus, elevated levels of TF positively correlate with the incidence of 
restenosis after percutaneous interventions, presumably due to promigratory effects 
of TF on vascular smooth muscle cells (Tutar et al., 2003). Despite the reduction in 
restenosis following deployment of drug eluting stents (DES) when compared to bare 
metal stents, stent thombosis rates have not been decreased with the use of DES 
and may even be higher (Iakovou et al., 2005). One possible explanation may be that 
the drugs eluting from the stents which are intended to inhibit restenosis by reduction 
of vascular smooth muscle cell migration and proliferation exert unwanted biological 
effects on these or other cell types in the vasculature, in particular endothelial cells. 
The drugs applied for coating the first and second generation stents, like rapamycin, 
everolimus, or zotarolimus, enhance TF expression in vascular cells and accelerate 
arterial thrombus formation via inhibition of the mTOR/p70S6K pathway (Camici et 
al., 2010; Steffel et al., 2005). Similarly, paclitaxel, another widespread stent coating 
drug was shown to increase endothelial TF expression and activity through activation 
of the MAP kinase JNK (Stahli et al., 2006). Hence, these findings may raise 
important issues in the context of drug eluting stent design since coating a stent with 
a drug exerting not only antiproliferative but also antithrombotic properties may offer 
new options in the interventional treatment of vascular disease. 
 
2.2.4. TF and cardiovascular risk factors 
Diabetes mellitus is associated with an increase in plasmatic TF activity (El-Ghoroury 
et al., 2008), TF antigen levels (Limet al., 2004), and TF containing microparticles 
(Diamant et al., 2002). In line with these observations, improvement of glycemic 
control or application of oral antidiabetics such as the peroxisome-proliferator-
activated receptor-γ agonist rosiglitazone downregulate TF protein expression 
(Golledge et al., 2007) in these patients. Consistent with this, high glucose increases 
TF antigen and activity in monocytes derived from healthy subjects (Stegenga et al., 
2006; Vaidyula et al., 2006). A similar effect of high glucose on TF expression was 
also observed in human endothelial cells (Boeri et al., 1989). In diabetes, 
hyperglycaemia induces the formation of advanced glycation end-products (AGE), 
which upregulate TF expression in endothelial cells and monocytes via nuclear factor 
kappa B (Bierhaus et al., 1997; Bierhaus et al., 1997; Kislinger et al., 2001). Not 
surprisingly, higher levels of AGE and TF were observed in the vasculature of 
diabetic mice, and blockade of the receptor for AGE significantly reduced the 
increased TF expression in the aorta of these mice (Kislinger et al., 2001).  
Patients with hyperlipidemia display an increased risk of developing thrombosis 
(Durrington, 2003). Elevated low density lipoprotein (LDL) levels are associated with 
an increased TF plasma activity (Sambola et al., 2003). Oxidized LDL triggers TF 
protein synthesis in monocytes (Wada et al., 1994), endothelial cells (Fei et al., 
1993), and vascular smooth muscle cells (Penn et al., 1999). In contrast, high-density 
lipoproteins (HDL) reduce the thrombin-induced TF expression in endothelial cells 
through PI3K pathway activation (Viswambharan et al., 2004). Moreover, 3-hydroxy-
3-methylglutaryl-CoA reductase inhibitors (statins) reduce TF expression in 
monocytes (Markle et al., 2003), endothelial cells (Eto et al., 2002), and vascular 
smooth muscle cells (Brandes et al., 2003). These findings have been confirmed by 
studies performed in ApoE-/- mice in which simvastatin and rosuvastatin treatment 
reduced TF antigen expression in atherosclerotic lesions independent of their lipid 
lowering effects (Bea et al., 2003; Monetti et al., 2007). Fibrates, which are also in 
use as lipid lowering drugs in the treatment of hyperlipidemia, also exert pleiotropic 
effects on vascular TF expression beyond their lipid lowering properties (Marx et al., 
2001). 
In contrast to normotensive subjects, hypertensive patients display increased plasma 
levels of TF antigen (Felmeden et al., 2003), which can be lowered by an appropriate 
antihypertensive management (Koh et al., 2004). Several mechanisms are thought to 
mediate this enhanced TF expression observed in arterial hypertension. For 
instance, the chronic exposure to shear stress induces the activation of transcription 
factors and consequently the expression of TF in endothelial cells (Dielis et al., 
2005). On the other hand, angiotensin II increases TF expression in monocytes (M. 
He et al.,, 2006), endothelial cells (Dielis et al., 2005), and vascular smooth muscle 
cells via the angiotensin II type 1 receptor. Consistent with this observation, ACE 
inhibitors and angiotensin II type 1 receptor antagonists reduce TF plasma activity in 
hypertensive patients and inhibit endotoxin-induced TF expression in monocytes 
(Napoleone et al., 2000).  
 
 
3. Therapeutic implications 
 
The fate of a forming thrombus is determined by the balance of numerous factors, 
including vessel wall, coagulation system, and aggregating platelets. In addition to 
the classical antithrombotic agents, drugs targeting TF and the TF:FVIIa complex 
have been developed, since targeting the initiation phase of thrombosis may prevent 
thrombus formation more efficiently. Considering the non-hemostatic properties of 
the TF:VIIa complex, inhibition of TF may also interfere with the pro-migratory and 
pro-proliferative effects of TF. 
Despite promising experimental studies suggesting an effective reduction in 
thrombosis with a lower bleeding risk as compared to other coagulation inhibitors 
such as heparin or direct thrombin inhibitors, approaches to inhibit TF not yet been 
applied successfully in humans, and further large scale clinical trials as well as novel 
concepts of delivery are required. 
 
3.1. Inhibition of TF production 
Inhibition of TF production can be achieved by genetic and pharmacological 
intervention at both the transcriptional and the post-transcriptional level (Fig. 3). 
Hairpin ribozymes degrade TF mRNA and decrease TF induction in vascular smooth 
muscle cells (Cavusoglu et al., 2002). Antisense oligonucleotides hybridize to the 
complementary TF mRNA sequence and thereby inhibit translation of the TF protein 
(Stephens & Rivers, 1997). Dimethyl sulfoxide, used for long-term storage of 
haematopoietic stem cells, inhibits arterial thrombus formation by impairing TF 
activity (Camici et al., 2006). Further, cardiac glycosides such as digoxin and ouabain 
inhibit TF translation by lowering the intracellular potassium concentration through 
impaired Na+/K+-ATPase activity (Stahli et al., 2007). Even more interesting, the 
class III anti-arrhythmic drug amiodarone inhibits the translation of the TF protein in 
human vascular cells and impairs arterial TF expression as well as arterial thrombus 
formation in mice in vivo (Breitenstein et al., 2008). These pleiotropic effects of 
amiodarone may at least in part account for the beneficial action of the drug on 
prognosis of patients with heart failure and coronary artery disease (Breitenstein et 
al., 2008). More recently, the phytosterole guggulsterone as well as the green tea 
polyphenol epigallocatechin-3-gallate, at concentrations detected in plasma after oral 
ingestion, were observed to inhibit TF induction through inhibition of MAP kinase 
activation in human vascular cells and to reduce TF expression in the carotid artery 
of mice in vivo (Gebhard et al., 2009; Holy, Stampfli et al., 2009). These studies 
demonstrate that both synthetic and naturally occurring drugs can inhibit the 
induction of TF in human vascular cells as well as thrombus formation in vivo. Such 
effects may at least in part account for the established beneficial actions of the above 
mentioned drugs on the prognosis of patients with cardiovascular disease. Hence, 
clinical trials assessing the application of these drugs in the context of TF inhibition 
and thrombus prevention should be performed. Ideally, the drugs would have to be 
applied in a targeted local manner in order to achieve a maximal effect in the vessel 
territory at risk for thrombosis while reducing systemic bleeding complications. 
 
3.2. Anti-TF antibodies 
Administration of anti-TF antibodies (Fig. 3) delays thrombus formation in a rabbit 
carotid thrombosis model and reduces the infarction area following ligation of 
coronary arteries (Erlich et al., 2000; Ragni et al., 1996). A clinical trial 
(PROXIMATE-TIMI 27) performed in 26 subjects suffering of stable coronary disease 
tested the impact of a chimeric monoclonal antibody targeting human TF at the factor 
X binding site (Sunol-cH36/ALT836) (Morrow et al., 2005). Preliminary results 
showed a dose dependent anticoagulant effect with only minor bleeding. Application 
of Sunol-cH36/ALT836 after endarterectomy in chimpanzees reduced local thrombus 
formation and improved vessel patency after 30 days without increasing bleeding 
time or surgical blood loss, indicating that early inhibition of coagulation with TF 
inhibitory antibodies reduces arterial thrombus formation effectively after vascular 
injury (Jiao et al., 2010).  
Considering the role of TF signalling in tumor angiogenesis, growth, and metastasis, 
inhibition of TF may also translate into anti-neoplastic effects. Indeed, administration 
of a monoclonal anti-TF antibody (CNTO 859) reduced breast cancer metastasis and 
tumor growth in xenograft models (Ngo et al., 2007). 
 
3.3. Recombinant tissue factor pathway inhibitor (rTFPI) 
TFPI is the physiological inhibitor of TF activity and the balance between TF and 
TFPI is critical for thrombus formation (Pedersen et al., 2005). By binding the active 
site of FXa, TFPI interferes with the activity of the TF:VIIa complex (Fig. 3). 
Administration of rTFPI inhibits thrombus formation at the site of balloon-induced 
arterial injury and reduces plaque thrombogenecity in humans (Badimon et al., 1999; 
Harker et al., 1996; St Pierre et al., 1999). In addition, local adenoviral 
overexpression of TFPI in arteries increases the resistance to thrombus formation 
(Nishida et al., 1999) and reduces intimal hyperplasia in injured vessels (Zoldhelyi et 
al., 2001). 
Despite of these positive actions, application of rTFPI may be limited because of its 
apoptotic effects observed in cultured endothelial and vascular smooth muscle cells, 
which may contribute to instability of atherosclerotic plaques (Fu et al., 2008; Hamuro 
et al., 1998). Moreover, a randomized controlled study including 1754 patients with 
severe sepsis and high international normal ratio (INR) found no effect on all-cause 
mortality (Abraham et al., 2003). Therefore, additional trials are needed with patients 
exhibiting cardiovascular diseases other than severe sepsis and being in a better 
general condition. 
 
3.4. Nematode anticoagulant protein (NAPc2) 
Recombinant nematode anticoagulant protein c2 (rNAPc2), isolated from the saliva 
of the haematophagous hookworm Ancylostoma caninum is a factor Xa dependent 
small protein inhibitor of the TF:VIIa complex which binds to a site on  factor Xa that 
is distinct from the catalytic centre (exo-site) (Fig. 3; Bergum et al., 2001). In a double 
blind placebo-controlled trial, rNAPc2 was found to be safe and well-tolerated at 
doses ranging from 0.3 to 5 μg/kg body weight in preventing thrombin generation 
during coronary angioplasty in combination with aspirin, clopidogrel, and heparin 
(Moons et al., 2003). A more recent phase II clinical study (ANTHEM-TIMI-32) 
demonstrated that in patients with non ST-elevation acute coronary syndrome 
managed with standard antithrombotics and an early invasive approach, additional 
proximal inhibition of the coagulation cascade with rNAPc2 was well tolerated and 
not associated with an increase in major or minor bleedings as compared with a 
placebo treatment (Fluture et al., 2007; Giugliano et al., 2007). A novel finding in the 
ANTHEM-TIMI-32 trial was that the doses of rNAPc2 suppressing thrombin 
generation through 48 h were associated with a ≥50% reduction in ischemia on 
continuous ECG. This provides a link between the mechanism of action of this drug 
and the hypothesized benefit in patients with plaque rupture and vessel wall injury. 
However, the trial was not powered for such an assessment and larger trials are 
required to confirm the hypothesis that rNAPc2 reduces clinical events. The fact that 
rNAPc2 has a half-life of 50 to 60 hours and can be administered subcutaneously, 
prolonged inhibition of thrombin generation by rNAPc2 for several weeks may have 
the potential to improve the recommended discharge regimen after ACS. However, 
immune responses after administration may limite its clinical application, since 
rNAPc2 is a non-human protein. Anti-rNAPc2 immunglobulins were indeed observed 
in one subject out of 20 patients receiving rNAPc2. Although these antibodies were 
not biologically active and without clinical relevance, the fact that they occurred in a 
high percentage of patients will have to be considered in future trials. 
 
 
 
 
 
 
4. Conclusions 
 
Major progress has been achieved in decrypting the biological effects and clinical 
relevance of TF in the context of cardiovacular disease. TF is a transmembrane 
glycoprotein, the main trigger of coagulation and, beyond this, an intracellular signal 
transducer. Several signalling pathways, specific for both the cell type and the 
stimulus, regulate TF induction and its cellular distribution. The discovery of blood-
borne TF has launched a new debate about its in vivo relevance, since the relative 
contribution of vessel-wall as compared to blood-borne TF for thrombus formation 
and propagation remains unclear. 
Elevated levels of TF activity are present in patients with cardiovascular risk factors 
and in subjects suffering of coronary artery disease. TF expression is up-regulated in 
atherosclerotic plaques, and cellular TF as well as extracellular TF contained in 
microparticles come in contact with the blood during endothelial erosion or plaque 
rupture. Therefore, TF contributes critically to the development of acute vascular 
events such as myocardial infarction or stroke. On the other hand, TF may promote 
the progression of atherosclerosis by enhancing vascular smooth muscle cell 
migration and proliferation. 
Since targeting the initiation phase of the clotting cascade may be more effective in 
preventing thrombus formation than at later stages, several strategies have been 
developed to inhibit TF expression or activity. Despite promising experimental 
results, the clinical benefit of these new approaches in comparison with current 
antithrombotic regimens remains to be demonstrated in large scale trials. Since the 
major part of TF activity is cell-associated and induced by vascular inflammation, a 
targeted local inhibition of TF may well prove to be the most effective approach with a 
minimal effect on the systemic balance of thrombosis and bleeding. 
Figure Legends 
 
Figure 1: 
TF exerts extracellular effects as main trigger of coagulation as well as intracellular 
effects on signal transduction. 
 
Figure 2: 
Expression of TF in different cell types during the pathogenesis of atherosclerotic 
lesions. 
 
Figure 3: 
Different approaches for inhibition of TF. 
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